PMID- 23462227
OWN - NLM
STAT- MEDLINE
DCOM- 20140310
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Sep
TI  - Assessment of baseline characteristics, glycemic control and oral antidiabetic 
      treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage 
      in Diabetes Management (REASON) Asia study.
PG  - 309-18
LID - 10.1111/1753-0407.12038 [doi]
AB  - BACKGROUND: To assess baseline characteristics, glycemic control, and treatment 
      with oral antidiabetic drugs (OAD) in type 2 diabetes mellitus (T2DM) patients. 
      METHODS: This multinational, observational study recruited patients >/= 21 years of 
      age who were newly diagnosed and/or treated with OAD monotherapy for <6 months 
      but were inadequately controlled. In cross-sectional phase, data on demographics, 
      medical history, diabetic complications and comorbidities, OAD treatment, 
      glycosylated hemoglobin (HbA1c), and fasting blood glucose (FBG) were collected. 
      In longitudinal phase evaluating 6-month follow-up of sulfonylurea (SU)-treated 
      patients, additional data on reasons for not achieving HbA1c targets were 
      collected. RESULTS: Of 1487 patients (mean [+/- SD] age 52.0 +/- 11.6 years; 46.7% 
      men; mean BMI 25.8 +/- 4.4 kg/m(2) ) recruited, 75.9% were newly diagnosed, 73.3% 
      had central obesity, 43.8% had hypertension, and 60.5% had dyslipidemia. The mean 
      HbA1c was 9.8 +/- 2.4%, and the mean FBG was 11.3 +/- 4.3 mmol/L. At T0 (baseline) 
      and T6 (month 6 visit), 99.8% (n=1066) and 97.1% (n=830) patients received SU, 
      respectively. There was decrease from T0 to T6 in mean HbA1c (10.2% vs 7.3%, 
      respectively; P<0.0001) and mean FBG (12.0 vs 7.6 mmol/L, respectively; 
      P<0.0001). Number of patients with HbA1c <7% increased from T0 (4.5%) to T6 
      (46.8%). Reasons for not achieving target HbA1c included poor diabetes education 
      (50.7%), non-compliance to OADs (21.4%), and fear of hypoglycemia (19.7%). 
      CONCLUSION: Marked reductions in HbA1c and FBG are achievable in T2DM patients 
      managed with OADs. However, patient education and compliance are important for 
      achieving and maintaining treatment targets.
CI  - (c) 2013 Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong 
      University School of Medicine.
FAU - Vichayanrat, Apichati
AU  - Vichayanrat A
AD  - Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 
      apichativ2000@yahoo.com
FAU - Matawaran, Bien J
AU  - Matawaran BJ
FAU - Wibudi, Aris
AU  - Wibudi A
FAU - Ferdous, Hossain S
AU  - Ferdous HS
FAU - Aamir, Azizul Hasan
AU  - Aamir AH
FAU - Aggarwal, Sanjay K
AU  - Aggarwal SK
FAU - Bajpai, Shailendra
AU  - Bajpai S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130528
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Asian People/statistics & numerical data
MH  - Blood Glucose/*metabolism
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/ethnology
MH  - Dyslipidemias/blood/complications/ethnology
MH  - Fasting/blood
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Hypertension/blood/complications/ethnology
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Obesity/blood/complications/ethnology
MH  - Patient Compliance/statistics & numerical data
MH  - Patient Education as Topic/statistics & numerical data
MH  - Registries/statistics & numerical data
MH  - Sulfonylurea Compounds/administration & dosage/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Asia
OT  - oral antidiabetic drugs
OT  - sulfonylurea
OT  - type 2 diabetes mellitus
OT  - 亚洲，口服降糖药，磺脲，2型糖尿病
EDAT- 2013/03/07 06:00
MHDA- 2014/03/13 06:00
CRDT- 2013/03/07 06:00
PHST- 2012/08/21 00:00 [received]
PHST- 2013/01/30 00:00 [revised]
PHST- 2013/02/21 00:00 [accepted]
PHST- 2013/03/07 06:00 [entrez]
PHST- 2013/03/07 06:00 [pubmed]
PHST- 2014/03/13 06:00 [medline]
AID - 10.1111/1753-0407.12038 [doi]
PST - ppublish
SO  - J Diabetes. 2013 Sep;5(3):309-18. doi: 10.1111/1753-0407.12038. Epub 2013 May 28.